Publication date context: February 15, 2026. A new clinical trial analyzes how intravenous oxytocin affects peripheral sensory afferents in acute pain, using microneurography. Supported by Wake Forest University Health Sciences, the National Institute of Neurological Disorders and Stroke and Linkoeping University, the study is listed as Recruiting on ClinicalTrials.gov. No results are reported yet, but the design details matter for regulatory review and device based measurement practices.
What changed in the trial design?
The study evaluates intravenous oxytocin versus intravenous placebo in an acute pain condition. The measure relies on microneurography to record peripheral sensory afferents. Sponsors are Wake Forest University Health Sciences, National Institute of Neurological Disorders and Stroke and Linkoeping University. Recruitment status is listed as recruiting.
What is being tested?
The intervention compares intravenous oxytocin with a placebo in adults with acute pain to assess effects on sensory nerve activity measured by microneurography.
What are the interventions?
Interventions include Drug: Intravenous Oxytocin and Drug: Intravenous Placebo as listed in the record.
How is the measurement performed?
Microneurography is used to record activity from peripheral sensory afferents in human subjects under acute pain conditions. The trial uses an intravenous oxytocin infusion to investigate potential effects relative to placebo, contributing to understanding of measurement approaches in pharmacologic studies.
What is microneurography?
Microneurography is a technique that records nerve activity in awake humans, enabling direct assessment of sensory fiber responses.
Why measure sensory afferents?
Measuring sensory afferents helps regulators assess the safety and performance of study methods that link pharmacologic intervention to nerve activity.
Who is involved and who funds the study?
Participants are studied in the context of acute pain. The study is sponsored by Wake Forest University Health Sciences, the National Institute of Neurological Disorders and Stroke and Linkoeping University. The project is currently recruiting as listed on ClinicalTrials.gov. The link to the registry is included in the source text.
Who funds or sponsors?
The record lists three sponsors: Wake Forest University Health Sciences, the National Institute of Neurological Disorders and Stroke and Linkoeping University.
What are the regulatory implications for device and trial oversight?
Findings from the record emphasize the need for clear documentation of intended purpose, measurement methodology and safety considerations when a pharmacologic intervention is evaluated with a device based measurement technique. The record shows an interventional drug study with a diagnostic microneurography component and multiple sponsor institutions, informing regulatory review processes.
FAQ
- 1. What is the study about? This study investigates the effects of intravenous oxytocin on peripheral sensory afferents using microneurography in acute pain.
- 2. What are the interventions? Intravenous oxytocin and intravenous placebo are used as the comparators.
- 3. Who funds the study? Wake Forest University Health Sciences, the National Institute of Neurological Disorders and Stroke, and Linkoeping University.
- 4. What is the recruitment status? The trial is listed as Recruiting.
- 5. Where can I learn more? The registry is ClinicalTrials.gov with the provided link.
Conclusion
In summary, the record outlines a phase of study into how intravenous oxytocin may influence peripheral nerve activity in acute pain using microneurography. The design underscores the role of sponsor oversight and regulatory considerations for device assisted measurements in pharmacology.
Disclaimer
This article is intended for professionals and does not constitute legal advice. It reflects information in the source text and does not set regulatory conclusions.
https://clinicaltrials.gov/study/NCT07409753?term=medical+device